Reason for request
Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code.
Clinical Benefit
| Substantial |
The Actual Benefit of XEROQUEL LP in the treatment of schizophrenia is substantial. |
Clinical Added Value
| no clinical added value |
XEROQUEL LP does not provide an Improvement in Actual Benefit (IAB level V) compared with other treatments available in this indication. |
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
6PFy5Zkp8QgW1kuC
Listen
